R B Perumpail, R J Wong, L D Ha, E A Pham, U Wang, H Luong, R Kumari, T J Daugherty, J P Higgins, Z M Younossi, W R Kim, J S Glenn, A Ahmed
We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression...
April 2015: Transplant Infectious Disease: An Official Journal of the Transplantation Society